Julia Rohrberg
ORCID: 0000-0001-6965-3905Pilot corpus only
This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.
Indexed papers
Why this DataRank?
An author's DataRank is the sum of the DataRanks of all 1 indexed paper attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.
Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.
Read the full methodology →Papers
Driven by 3 papers. Top paper: “A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.”.
Amelia S. Gliwa, Siti Rahmaputri, H Dittrich, Melanie Majure, Hope S. Rugo +10 more
Daniel Van de Mark, Meelad Amouzgar, Joyce V. Lee, Moufida Taileb, Alexandra Corella +13 more
Julia Rohrberg, Andrei Goga, Rebecca Heald, Guadalupe E. Pena